Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

Presentation TCT 2016

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Presenter: Jonathan M. Hill, Christoph K. Naber, Manel Sabate

November 01, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

Stable CAD With Substantial Ischemia and No-to-Mild Symptoms: Initial Revascularization vs Medical Therapy

Presenter: William A. Gray, Gregg W. Stone, D. Christopher Metzger, Sripal Bangalore

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

I Believe That Most PCI Procedures for Stable CAD Are NOT Worth the Time/Effort/Risk/Money!

Presenter: Eric R. Bates, Spencer B. King III, Sanjay Kaul

October 13, 2015

News Conference News TCT 2015

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

October 13, 2015

News Conference News TCT 2015

PLATFORM: FFRCT Reduces Costs Compared With Invasive Coronary Angiography

October 13, 2015

$Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!$

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee

October 12, 2015

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas

October 12, 2015

Presentation TCT 2015

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Presenter: John A. Bittl, Robert A. Harrington, Mahesh Madhavan

October 12, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Advertisement

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Stable CAD With Substantial Ischemia and No-to-Mild Symptoms: Initial Revascularization vs Medical Therapy

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

I Believe That Most PCI Procedures for Stable CAD Are NOT Worth the Time/Effort/Risk/Money!

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

PLATFORM: FFRCT Reduces Costs Compared With Invasive Coronary Angiography

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content